Date:
October 4, 2021
Issue #:
1634
Summary:
Insulin glargine-yfgn (Semglee – Viatris), a follow-on
insulin glargine product, has now received
interchangeability status with the reference product
Lantus from the FDA. It is the first biosimilar insulin
product to receive this designation in the US. Now a
pharmacist can substitute Semglee for Lantus as a
lower-cost alternative without permission from the
prescriber.
insulin glargine product, has now received
interchangeability status with the reference product
Lantus from the FDA. It is the first biosimilar insulin
product to receive this designation in the US. Now a
pharmacist can substitute Semglee for Lantus as a
lower-cost alternative without permission from the
prescriber.
